Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 724-730 , November 2011

Impact of radiofrequency ablation on PBMC subpopulation in patients with renal cell carcinoma

  • Marcin Matuszewski, Ph.D.

      Affiliations

    • Department of Urology, Medical University of Gdańsk, Gdańsk, Poland
    • ,
  • Jerzy Michajłowski, M.D.

      Affiliations

    • Department of Urology, Medical University of Gdańsk, Gdańsk, Poland
    • Corresponding Author InformationCorresponding author. Tel./fax: +48-058-349-38-24
    • ,
  • Igor Michajłowski, M.D.

      Affiliations

    • Department of Dermatology and Venerology, Medical University of Gdańsk, Gdańsk, Poland
    • ,
  • Katarzyna Ruckermann-Dizurdzińska, Ph.D.

      Affiliations

    • Department of Pathophysiology, Medical University of Gdańsk, Gdańsk, Poland
    • ,
  • Jacek M. Witkowski, Ph.D.

      Affiliations

    • Department of Pathophysiology, Medical University of Gdańsk, Gdańsk, Poland
    • ,
  • Wojciech Biernat, Ph.D.

      Affiliations

    • Department of Neuropathology and Molecular Pathology, Medical University of Gdańsk, Gdańsk, Poland
    • ,
  • Kazimierz Krajka, Ph.D.

      Affiliations

    • Department of Urology, Medical University of Gdańsk, Gdańsk, Poland

Received 16 June 2009 ,Revised 7 September 2009 ,Accepted 20 November 2009.

References 

  1. Zlotta AR, Wildschutz T, Raviv G, et al. Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: Ex vivo and in vivo experience. J Endourol. 1997;11:251–258
  2. McGovern FJ, Wood BJ, Goldberg SN, et al. Radio frequency ablation of renal cell carcinoma via image guided needle electrodes. J Urol. 1999;161:599–600
  3. Mahnken AH, Rohde D, Brkovic D, et al. Percutaneous radiofrequency ablation of renal cell carcinoma: Preliminary results. Acta Radiol. 2005;46:208–214
  4. Veltri A, Calvo A, Tosetti I, et al. Experiences in US-guided percutaneous radiofrequency ablation of 44 renal tumors in 31 patients: Analysis of predictors for complications and technical success. Cardiovasc Intervent Radiol. 2006;29:811–818
  5. Mouraviev V, Joniau S, Van Poppel H, et al. Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Eur Urol. 2007;51:328–336
  6. Nikfarjam M, Muralidharan V, Christophi C. Mechanisms of focal heat destruction of liver tumors. J Surg Res. 2005;127:208–223
  7. Wissniowski TT, Hansler J, Neureiter D, et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res. 2003;63:496–500
  8. Zerbini A, Pilli M, Penna A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006;66:1139–1146
  9. Hansler J, Wissniowski TT, Schuppan D, et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol. 2006;12:3716–3721
  10. Ali MY, Grimm CF, Ritter M, et al. Activation of dendritic cells by local ablation of hepatocellular carcinoma. J Hepatol. 2005;43:817–822
  11. Napoletano C, Taurino F, Biffoni M, et al. RFA strongly modulates the immune system and anti-tumor immune response in metastatic liver patients. Int J Oncol. 2008;32:481–490
  12. den Brok MH, Sutmuller RP, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64:4024–4029
  13. Rughetti A, Rahimi H, Rossi P, et al. Modulation of blood circulating immune cells by radiofrequency tumor ablation. J Exp Clin Cancer Res. 2003;22:247–250
  14. Yu HC, Moon JI, Jin ZW, et al. Effect of radiofrequency ablation of the liver on cell mediated immunity in rats. World J Surg. 2005;29:739–743
  15. de Reijke TM, Bellmunt J, van Poppel H, et al. EORTC-GU group expert opinion on metastatic renal cancer. Eur J Cancer. 2009;45:765–773
  16. Hansler J, Neureiter D, Strobel D, et al. Cellular and vascular reactions in the liver to radio-frequency thermo-ablation with wet needle applicators (Study on juvenile domestic pigs). Eur Surg Res. 2002;34:357–363
  17. Bartholomae WC, Rininsland FH, Eisenberg JC, et al. T cell immunity induced by live, necrotic, and apoptotic tumor cells. J Immunol. 2004;173:1012–1022
  18. Gleimer M, Parham P. Stress management: MHC class I and class I-like molecules as reporters of cellular stress. Immunity. 2003;19:469–477
  19. Schueller G, Kettenbach J, Sedivy R, et al. Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo. Int J Oncol. 2004;24:609–613
  20. Rai R, Richardson C, Flecknell P, et al. Study of apoptosis and heat shock protein (HSP) expression in hepatocytes following radiofrequency ablation (RFA). J Surg Res. 2005;129:147–151
  21. Pilla L, Squarcina P, Coppa J, et al. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res. 2005;65:3942–3949
  22. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol. 2005;6:593–599

☆ This work was funded by the Polish Ministry of Science and grant NN403181834 to J.M.

PII: S1078-1439(09)00374-3

doi: 10.1016/j.urolonc.2009.11.021

Urologic Oncology: Seminars and Original Investigations
Volume 29, Issue 6 , Pages 724-730 , November 2011

Article Tools

* Image Usage & Resolution